Nav: Home

Ticagrelor after MI: Added benefit called into question by data subsequently submitted

October 07, 2016

The drug ticagrelor has been approved since February 2016 for adults who had a myocardial infarction a year or more ago and are at a high risk of a new myocardial infarction or stroke. Ticagrelor is used together with low-dose acetylsalicylic acid (ASA). In its dossier assessment published in early July 2016, the German Institute for Quality and Efficiency in Health Care (IQWiG) determined an indication of a minor added benefit of ticagrelor in comparison with the administration of ASA alone.

On the inclusion of additional analyses that the drug manufacturer provided in the commenting procedure conducted by the Federal Joint Committee (G-BA), the Institute now came to a different conclusion, however: An added benefit is not proven because positive effects are called into question by negative effects.

Non-severe bleeding notably more common

The dossier had only contained data on severe bleeding. There were no data on non-severe bleeding that are clinically relevant. The results of the analyses subsequently submitted by the manufacturer were to the disadvantage of ticagrelor: Since these bleeding events were notably more common than under ASA monotherapy, IQWiG determined proof of greater harm with the extent "considerable".

No data on quality of life

In addition, there were no data on quality of life. Particularly in coronary heart disease (CHD), this is a very important outcome criterion however, which is even more important in view of side effects such as dyspnoea. "Disease-related quality of life" is the first treatment goal listed in the recently published revised version of the National Care Guideline for Coronary Heart Disease.

Since, on the one hand, greater harm was proven for an additional outcome, and, on the other, no data on quality of life were available, the positive effects, including the ones regarding mortality and late complications, were called into question by the negative effects. In the overall consideration, no added benefit of ticagrelor plus ASA in comparison with ASA monotherapy could be derived from the data.
G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the manufacturer submitted additional information in the commenting procedure. The G-BA then commissioned IQWiG to assess the data subsequently submitted. IQWiG now presents this assessment in the form of an addendum. The G-BA makes a final decision on the extent of added benefit.

The English translation of the addendum will be published soon. If you would like to be informed when this document is available, please send an e-mail to

Institute for Quality and Efficiency in Health Care

Related Coronary Heart Disease Articles:

New study highlights smoking intensity in coronary heart disease risk
Increased relative risks for coronary heart disease (CHD) have long been associated with smoking, and traditionally they have been dependent on the number of cigarettes smoked a day, smoking intensities, and total exposure over time.
Pessimism associated with risk of death from coronary heart disease
Pessimism seems to be a strong risk factor for death from coronary heart disease, while optimism does not protect from it, according to a study published in the open-access journal BMC Public Health that involved 2,267 middle-aged and older Finnish men and women.
Study finds large decrease in coronary heart disease in US
The incidence of coronary heart disease in the US declined nearly 20 percent from 1983 to 2011, according to a study appearing in the Nov.
Study of Israelis & Palestinians rethinks how HDL protects against coronary heart disease
Studying a population of Israelis and Palestinians, researchers from the Hebrew University of Jerusalem found that medium-sized HDL particles (MS-HDL-P) and the number of HDL particles (HDL-P) are better markers of coronary artery disease than high-density lipoprotein cholesterol (HDL-C).
Americans are getting heart-healthier: Coronary heart disease decreasing in the US
Coronary heart disease is one of the leading causes of death in the United States.
Little cost difference between tests to diagnose coronary heart disease
For patients with suspected coronary artery disease, computed tomographic angiography and functional diagnostic testing strategies have similar costs through three years of follow up.
Study shows minorities had lower risk of coronary heart disease than whites
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
The evidence for saturated fat and sugar related to coronary heart disease
Atherosclerotic Coronary Heart Disease (CHD) is responsible for one in every six deaths in the United States as well as being the leading cause of death throughout the developed world.
Coronary heart disease patients with no teeth have nearly double risk of death
Coronary heart disease patients with no teeth have nearly double the risk of death as those with all of their teeth, according to research published today in the European Journal of Preventive Cardiology.
Shorter height is directly associated with increased risk of coronary heart disease
A University of Leicester-led study uses genetic approach to show link between height and disease.

Related Coronary Heart Disease Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...